AC Immune has filed a patent for novel compounds targeting the NLRP3 inflammasome pathway to treat diseases by modulating IL-1 beta and/or IL-18 levels. The invention focuses on compounds capable of inhibiting the activation of NLRP3 inflammasome, offering potential therapeutic benefits. GlobalData’s report on AC Immune gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AC Immune, Neuro-degenerative receptor binding drug compositions was a key innovation area identified from patents. AC Immune's grant share as of January 2024 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Novel compounds for treating diseases by modulating nlrp3 inflammasome pathway
See Also:
The patent application (Publication Number: US20240034735A1) discloses a series of compounds represented by formulas (I), (I'), (Ia), (Ib), (Ic), (Id), and (Ie) for use in the treatment, alleviation, or prevention of diseases related to the NLRP3 inflammasome pathway. The compounds are designed to modulate components of the NLRP3 inflammasome pathway and regulate levels of IL-1 beta and IL-18. The patent covers the compounds themselves, as well as pharmaceutical compositions containing them, for administration to individuals in need of such treatment.
Furthermore, the patent application outlines a method for the treatment of various diseases and disorders responsive to the modulation of the NLRP3 inflammasome pathway, including Alzheimer's disease, Parkinson's disease, multiple sclerosis, asthma, rheumatoid arthritis, diabetes, and various inflammatory conditions. The method involves administering an effective amount of the disclosed compounds or their derivatives to individuals suffering from these conditions. Additionally, the patent application includes provisions for in vitro screening and analytical reference methods using the compounds for research and diagnostic purposes. Overall, the patent application aims to provide a novel approach to targeting the NLRP3 inflammasome pathway for therapeutic intervention in a wide range of diseases and conditions.
To know more about GlobalData’s detailed insights on AC Immune, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
